The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| RANI | -17.06% | N/A | N/A | -81% |
| S&P | +14.5% | +93.32% | +14.09% | +52% |
Rani Therapeutics Holdings, Inc. engages in the operation of a clinical stage bio-therapeutics company. The company was founded by Mir Imran on February 21, 2012 and is headquartered in San Jose, CA.
A game-changing pill from Rani Therapeutics may offer an easier alternative to fight debilitating diseases.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.24M | 5.9% |
| Gross Margin | -45.93% | 0.0% |
| Market Cap | $17.25M | -82.7% |
| Market Cap / Employee | $0.16M | 0.0% |
| Employees | 105 | -25.0% |
| Net Income | -$11.22M | 16.0% |
| EBITDA | -$10.27M | 16.3% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $10.72M | 113.7% |
| Accounts Receivable | $0.00M | 0.0% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $5.43M | -74.9% |
| Short Term Debt | $16.19M | 18.6% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -97.93% | -49.9% |
| Return On Invested Capital | -74.88% | -11.2% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$5.83M | 36.1% |
| Operating Free Cash Flow | -$5.80M | 35.8% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 20.18 | 13.09 | 21.14 | -5.65 | -141.80% |
| Price to Sales | 43.53 | 35.11 | 15.65 | - | |
| Price to Tangible Book Value | 20.18 | 13.09 | 21.15 | -5.65 | -141.80% |
| Enterprise Value to EBITDA | -5.87 | -4.36 | -4.18 | -2.54 | -70.73% |
| Return on Equity | -227.1% | -272.5% | -404.1% | -1372.6% | 690.84% |
| Total Debt | $33.73M | $29.71M | $25.67M | $21.62M | -38.67% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
